Patents by Inventor Alessandra Vitaliti
Alessandra Vitaliti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220184074Abstract: The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.Type: ApplicationFiled: May 20, 2020Publication date: June 16, 2022Inventors: Souvik BHATTACHARYA, Bruno BIETH, Maciej CABANSKI, Bruno CENNI, Stefan DE BUCK, Martin KAUL, Arvind KINHIKAR, Andrijana RADIVOJEVIC, Thomas SEVERIN, Julian STORIM, Alessandra VITALITI GARAMI
-
Publication number: 20220175772Abstract: The present disclosure relates to methods for treating Sjögren's Syndrome disease using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Sjögren's Syndrome patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.Type: ApplicationFiled: May 20, 2020Publication date: June 9, 2022Inventors: Souvik BHATTACHARYA, Bruno BIETH, Maciej CABANSKI, Bruno CENNI, Stefan DE BUCK, Martin KAUL, Arvind KINHIKAR, Andrijana RADIVOJEVIC, Alessandra VITALITI GARAMI
-
Patent number: 8758754Abstract: The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant <1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system.Type: GrantFiled: March 16, 2012Date of Patent: June 24, 2014Assignee: Novartis AGInventors: Carmen Barske, Stefan Frentzel, Anis Khurso Mir, Martin E. Schwab, Alessandra Vitaliti Garami
-
Patent number: 8535666Abstract: This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant, 1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.Type: GrantFiled: June 18, 2010Date of Patent: September 17, 2013Assignees: Novartis AG, Universitat ZurichInventors: Carmen Barske, Anis Khusro Mir, Thomas Oertle, Lisa Schnell, Martin E. Schwab, Alessandra Vitaliti, Mauro Zurini
-
Publication number: 20120171215Abstract: The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant <1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system.Type: ApplicationFiled: March 16, 2012Publication date: July 5, 2012Applicants: University of Zurich, Novartis AGInventors: Carmen Barske, Stefan Frentzel, Anis Khusro Mir, Martin E. Schwab, Alessandra Vitaliti Garami
-
Patent number: 8163285Abstract: The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant<1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system.Type: GrantFiled: October 27, 2008Date of Patent: April 24, 2012Assignee: Novartis AGInventors: Carmen Barske, Stefan Frentzel, Anis Khusro Mir, Martin E. Schwab, Alessandra Vitaliti Garami
-
Publication number: 20110059110Abstract: This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant, 1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.Type: ApplicationFiled: June 18, 2010Publication date: March 10, 2011Inventors: Carmen Barske, Anis Khusro Mir, Thomas Oertle, Lisa Schnell, Martin E. Schwab, Alessandra Vitaliti, Mauro Zurini
-
Publication number: 20110027284Abstract: The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG with a dissociation constant<1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system; a pharmaceutical composition comprising said binding molecule; and a method of treatment of a disease of the peripheral (PNS) and/or central (CNS) nervous system.Type: ApplicationFiled: October 27, 2008Publication date: February 3, 2011Applicants: NOVARTIS AG, UNIVERSITY OF ZURICHInventors: Carmen Barske, Stefan Frentzel, Anis Khurso Mir, Martin E. Schwab, Alessandra Vitaliti
-
Publication number: 20110008334Abstract: The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG or human NiG-D20 or human NogoA_342-357 with a dissociation constant, 1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of a nerve repair, a pharmaceutical composition comprising said binding molecule; and a method of treatment of nerve repair; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with nerve repair.Type: ApplicationFiled: June 16, 2010Publication date: January 13, 2011Applicant: Novartis Pharma AGInventors: Carmen Barske, Stefan Frentzel, Anis Khusro Mir, Martin E. Schwab, Alessandra Vitaliti
-
Patent number: 7785593Abstract: This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant <1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.Type: GrantFiled: December 9, 2003Date of Patent: August 31, 2010Assignees: Novartis AG, University of ZurichInventors: Carmen Barske, Anis Khusro Mir, Thomas Oertle, Lisa Schnell, Martin E. Schwab, Alessandra Vitaliti, Mauro Zurini
-
Publication number: 20090181023Abstract: The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG or human NiG-D20 or human NogoA_342-357 with a dissociation constant <1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide capable of producing a binding molecule; an isolated host cell which comprises an expression system as defined above; the use of such binding molecule as a pharmaceutical, especially in the treatment of nerve repair; a pharmaceutical composition comprising said binding molecule; and a method of treatment of diseases associated with nerve repairType: ApplicationFiled: September 17, 2004Publication date: July 16, 2009Inventors: Carmen Barske, Stefan Frentzel, Anis Khusro Mir, Martin E. Schwab, Alessandra Vitaliti
-
Publication number: 20060183678Abstract: This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant <1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.Type: ApplicationFiled: December 9, 2003Publication date: August 17, 2006Inventors: Carmen Barske, Anis Mir, Thomas Oertle, Lisa Schnell, Martin Schwab, Alessandra Vitaliti, Mauro Zurini